Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
Christina N. Bennett(National Institutes of Health), Jeffrey E. Green(National Institutes of Health)
Cited by 33